Eight versus twelve weeks of sofosbuvir-velpatasvir in treatment-naïve non-cirrhotic patients with chronic hepatitis C virus infection: Study protocol for a multicentric, open labelled, randomized, non-inferiority trial (RESOLVE trial)

BACKGROUND: Hepatitis C virus (HCV) is a common cause of liver cirrhosis and hepatocellular carcinoma. Globally, nearly 71 million people have chronic HCV infection, and approximately 399,000 dies annually. In patients without cirrhosis, HCV infection is treated with 12 weeks of sofosbuvir/velpatasv...

Descripción completa

Detalles Bibliográficos
Autores principales: Awasthi, Ashish, Katiyar, Harshita, Rungta, Sumit, Deep, Amar, Kumar, Vinod, Shalimar, Kumar, Ajay, Tiwari, Prachi, Goel, Amit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10194938/
https://www.ncbi.nlm.nih.gov/pubmed/37200346
http://dx.doi.org/10.1371/journal.pone.0285725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10194938/
https://www.ncbi.nlm.nih.gov/pubmed/37200346
http://dx.doi.org/10.1371/journal.pone.0285725

Ejemplares similares